• Information

Yuki Shimahara from LPixel Featured in Forbes Asia 30 Under 30 2017

Tokyo, Japan ― April 13, 2017 ― LPixel Inc., a leader in image processing and analysis technology in life science and medical research, is pleased to announce that the company CEO Yuki Shimahara was featured in Forbes Asia 30 under 30, a publication which highlights the top venture capitalists who are under the age of 30.

Forbes 30 Under 30 is a set of lists issued annually by Forbes magazine that features 300 young leaders and entrepreneurs from all across Asia. The list includes 30 candidates selected from each of the ten categories including Entertainment & Sports, Enterprise, and Consumer Technology. LPixel CEO, Yuki Shimahara was selected as the feature honoree for the Health & Science category.

▼Forbes 30 Under 30 Asia 2017 Healthcare & Science

▼Forbes 30 Under 30 Asia 2017 Yuki Shimahara

About Yuki Shimahara
Majoring in the life sciences, Yuki completed his master’s degree at the University of Tokyo. During his studies, Yuki received the bronze prize at the iGEM which was held at MIT. Upon completing his research on artificial photosynthesis, Yuki continued his research in cell organelle image analysis and simulation. Yuki started his career at GREE Inc., where he took part in business strategy and human resources management. At the second IT firm, Yuki gained experience in global business development, working with partners in Asia and western countries. He later established LPixel Inc. in March 2014 along with his two colleagues studying in the same university laboratory. Yuki was also selected to join the Next Innovator 2015 Project in Silicon Valley, which was hosted by the Japan Ministry of Economy, Trade and Industry.

About LPixel
LPixel is a leader in advanced image analysis and processing technology encompassing the life science field. Founded in March 2014, LPixel is dedicated to offering research facilities top-tier image analysis technologies and medical diagnosis support systems, both of which adopt advanced AI technology. The company is currently working with the National Cancer Center Japan and other research institutions to further the development of AI-based medical diagnosis software. For more information, please visit


Cutting-Edge Technologies that Lead Future Medical Diagnosis
EIRL analyzes a wide range of medical data to provide an accurate and efficient diagnosis. EIRL aims to be the closest partner to all doctors, and serve as another powerful set of eyes to provide top quality medical care.
AI Accelerating
Phase R&D
IMACEL, an image analysis AI, helps to solve various issues in the drug discovery process.
Life science and AI experts support successful AI implementation.



Alphabetical listing


A Third Career Option for Researchers